Background
==========

Multiple acyl-CoA dehydrogenase deficiency (MADD, MIM \#231680), also called glutaric aciduria type 2 (GA2), is an inborn error of metabolism affecting the oxidation of fatty acids as well as the catabolism of branched-chain amino acids, lysine and tryptophan. MADD is caused by deficiency of either an electron-transfer flavoprotein (ETF, encoded by *ETFA* and *ETFB*) or an electron-transfer flavoprotein dehydrogenase (ETFDH, encoded by *ETFDH*). Inheritance follows an autosomal recessive trait \[\[[@B1]\]\]. The metabolic defects result in impaired adenosine triphosphate (ATP) biosynthesis, excessive lipid accumulation in different organs and insufficient gluconeogenesis \[\[[@B1]\]\]. The clinical phenotype is heterogeneous and has been classified into three groups: neonatal onset with congenital anomalies (type 1), neonatal onset without anomalies (type 2), and mild and/or later onset (type 3) \[\[[@B1]\],\[[@B2]\]\]. While neonates usually present with severe metabolic decompensations including metabolic acidosis, non-ketotic hypoglycemia, hyperammonemia, hypotonia, coma and cardiomyopathy, the course and age at presentation of later-onset forms is extremely variable. In adolescents and adults, muscular or cardiac symptoms or episodic vomiting are usually first features suggestive for MADD \[\[[@B1]\],\[[@B3]\]-\[[@B9]\]\]. Therapeutic management mostly comprises a diet restricted in fat and protein and the avoidance of fasting. The majority of patients respond well to riboflavin therapy.

Diagnosis is based on both the urinary organic acid profile and the acylcarnitine pattern in dried blood/plasma. The characteristic urinary organic acid pattern comprises elevated levels of glutaric, ethylmalonic, 3-hydroxyisovaleric, 2-hydroxyglutaric, 5-hydroxyhexanoic, adipic, suberic, sebacic, and dodecanedioic acid without relevant ketonuria, especially if combined with glycine conjugates of C4 and C5 acids \[\[[@B1]\]\]. Acylcarnitine analysis usually reveals increased concentrations of several short-, medium- and long-chain acylcarnitines, such as C4, C5, C5-DC, C6, C8, C10, C12, C14:1, C16, C18:1 \[\[[@B10]\]\]. However, the diagnosis may be challenging in late-onset cases since the biochemical abnormalities may be mild, atypical or only detectable during metabolic decompensations. This report aims at providing a comprehensive description of late-onset MADD in its clinical and genetic heterogeneity by analysis of all cases published to date.

Methods
=======

A systematic literature search in PubMed was performed using the terms "multiple acyl-CoA dehydrogenase deficiency", "glutaric aciduria type 2", "glutaric acidemia type 2", "ETFDH", "ETFA" and "ETFB" in order to obtain comprehensive information on the clinical course of MADD patients with late onset of the disease (type 3). Late onset was defined as onset beyond the neonatal period (\>28 days). The search was performed in January 2014. 350 cases of late-onset MADD published between 1979 and 2014 were identified (for detailed data and references see Additional file [1](#S1){ref-type="supplementary-material"}: Table S1). All cases were evaluated and analyzed with a special focus on the patients' age at onset, age at diagnosis, symptoms, biochemical abnormalities, affected genes and response to riboflavin treatment. Riboflavin responsiveness was defined as a positive clinical response to treatment with improvement of symptoms, not only biochemical parameters.

Results
=======

350 cases of late-onset MADD were reviewed. Detailed information on all patients is displayed in the Additional file [1](#S1){ref-type="supplementary-material"}: Table S1 as well as in Table [1](#T1){ref-type="table"}. 144 patients were female, 177 male, the sex of 29 individuals was not reported. Mean age at onset was 19.2 years (n = 273, range 0.13-68 years) (Figure [1](#F1){ref-type="fig"}). Seven patients were identified by newborn screening, and another 5 patients were diagnosed by early investigations in the neonatal period due to an affected sibling. In 2 patients the diagnosis was only made post mortem. Mean age at diagnosis of symptomatic patients was 17.6 years (n = 111, median 14.0 years, range 0.13-69 years). The mean delay between onset of symptoms and diagnosis was 3.9 years (n = 93, range 0-29 years). If only patients without acute decompensations were considered (n = 38), the mean latency was 3.7 years (range 0-29 years). 33.1% of patients (111/335) displayed acute signs and symptoms, i.e., metabolic decompensations with hypoglycemia and acidosis, while chronic features were reported in 85.3% (291/341) of patients. Chronic manifestations mainly comprised muscular weakness, exercise intolerance and muscle pain. 20.4% (68/333) had both, acute episodes and chronic symptoms. 5.2% (18/349) of patients had already died when reported in the literature (mean age at death 5.8 years, range 0.2-20 years). Among those only the minority (4/14, 28.6%) deceased during the initial metabolic crisis. In 5 of 11 patients with fatal outcome of whom detailed data were available, the diagnosis was known before the life-ending event. Three of those had been identified by newborn screening or early neonatal screening due to an affected older sibling while two patients had been diagnosed symptomatically in infancy/childhood. In the remaining 6 patients the diagnosis was only made during the fatal metabolic decompensation or post mortem. 2.6% (9/349) of patients have remained asymptomatic until a mean age of 6.15 years (0.5-14.0 years).

###### 

Clinical information on 350 patients with late-onset MADD published in the literature

  --------------------------------- ---------------------------------------------------
  Sex                               Female n = 144, male n = 177, not reported n = 29
  Identified by newborn screening   2.0% (7/350) patients
  Identified by family screening    1.4% (5/350) patients
  Acute symptoms                    33.1% (111/335) of patients
  Chronic symptoms                  85.3% (291/341) of patients
  Acute and chronic symptoms        20.4% (68/333) of patients
  Mean age at onset of symptoms     19.2 years (n = 273)
  Mean diagnostic delay             3.9 years (0-29 years)
  Asymptomatic                      2.6% (9/349) of patients
  Deceased patients                 5.2% (18/349) of patients
  Riboflavin responsiveness         98.4% (256/260) of patients
  --------------------------------- ---------------------------------------------------

![**Age at onset in 146 late-onset MADD patients.** Age at onset of symptoms ranges from early infancy to late adulthood. The mean age at onset of 146 patients with late-onset MADD of whom detailed information was given in the literature is 14.3 years. Of additional 56 cases reported by Wang et al. \[\[[@B55]\]\] and 71 cases reported by Xi et al. \[\[[@B28]\]\] only the mean age at onset (24.5 ± 12.6 years with a range from 4 to 55 years and 25.0 ± 13.3 years with a range from 4 to 36 years, respectively) is known. If these cases are also taken into account, the mean age at onset in this study cohort is 19.2 years.](s13023-014-0117-5-1){#F1}

Results of organic acid analysis in urine were available in 258 patients. A typical metabolite pattern was detected at least once in 236/258 patients (91.5%) while only unremarkable organic acid results were reported in 22/258 individuals (8.5%). In some cases, elevated signals of only single metabolites such as ethylmalonic acid or glutaric acid were detected \[\[[@B11]\]-\[[@B13]\]\]. Some patients displayed a pathognomonic metabolite pattern only intermittently, i.e. during metabolic decompensations. In several patients, the initially detected biochemical abnormalities disappeared under treatment with riboflavin. Acylcarnitine profiles were at least intermittently characteristic for MADD in 201/214 patients (93.9%). In 13/214 individuals (6.1%) only normal acylcarnitine profiles were reported. Again, in some patients an abnormal acylcarnitine pattern was only found during metabolic decompensations or after a prolonged exercise test.

Among 260 patients of whom data on riboflavin therapy were available, 256 (98.4%) were reported to be clearly riboflavin-responsive, while in 2 patients efficacy of riboflavin therapy was only partial with merely "some improvement" of the muscular symptoms \[\[[@B14]\],\[[@B15]\]\]. In one of these patients riboflavin supplementation was discontinued later because of limited efficacy \[\[[@B14]\]\]. In one other patient in whom riboflavin therapy was started during severe metabolic decompensation fatal outcome could not be prevented \[\[[@B16]\]\]. Only one patient was reported to be clearly unresponsive to riboflavin \[\[[@B17]\]\].

The genotype was reported of 245 patients. The vast majority carried mutations in the *ETFDH* gene (228/245, 93.1%), while in only few patients *ETFA* and *ETFB* mutations were detected (11/245, 4.5% and 6/245, 2.4% of patients, respectively) (Figure [2](#F2){ref-type="fig"}). In one patient, no mutation was identified in the *ETFA* and *ETFB* genes, while the *ETFDH* gene was not studied. In 2 patients, no mutations could be delineated despite analyzing of the entire coding regions and flanking intronic sequences of the *ETFA, ETFB* and *ETFDH* genes \[\[[@B18]\],\[[@B19]\]\].

![**Mutated genes in 245 patients with late-onset MADD.** The majority of late-onset MADD patients harbor mutations in the *ETFDH* gene. The frequency of *ETFDH, ETFA* and *ETFB* mutations in 245 patients with late-onset MADD is displayed.](s13023-014-0117-5-2){#F2}

Discussion
==========

This evaluation of all published cases of late-onset MADD characterizes the clinical and genetic heterogeneity of this disorder with a special focus on typical symptoms, the diagnostic work-up and therapeutic options. The clinical phenotype of late-onset MADD is highly variable and ranges from acute, in some cases even fatal metabolic crises in infancy to asymptomatic adults. Even within the same family the clinical picture can vary profoundly \[\[[@B20]\],\[[@B21]\]\]. Although most patients become symptomatic within the first two decades, onset of symptoms ranges from the second month of life to late adulthood. The vast majority of patients presented with chronic, mainly myopathic symptoms. Nevertheless, one third of patients also displayed acute symptoms or metabolic decompensations which may be life-threatening if not treated adequately. Although these decompensations mostly occur in childhood, severe metabolic crises in adulthood have also been described \[\[[@B14]\],\[[@B22]\]-\[[@B26]\]\]. Decompensations are characterized by acidosis, hypoglycemia, elevated activities of transaminases, rhabdomyolysis with raised creatine kinase activity, and, eventually, hyperammonemia. These episodes are usually triggered by catabolic states, either due to infections and febrile illnesses or to a reduced energy supply. However, in adulthood, other triggering factors like operations, low-energy diets or weight loss of other reasons, alcohol, valproate therapy, pregnancy or labor may also play a role \[\[[@B9]\],\[[@B15]\],\[[@B24]\],\[[@B27]\]\]. Chronic features include exercise intolerance, muscle weakness, muscle wasting and muscular pain. Some cases may develop respiratory insufficiency \[\[[@B13]\],\[[@B23]\],\[[@B28]\]\], while rhabdomyolysis is not often seen. Muscle biopsies usually reveal lipid storage myopathy (Figure [3](#F3){ref-type="fig"}). Especially in adult cases, diagnosis is often not straight-forward, resulting in a significant diagnostic delay. One patient has been diagnosed as late as 29 years after the onset of symptoms. Surprisingly, the diagnostic delay was not less pronounced in patients with acute symptoms. For patients with acute decompensations early diagnosis and treatment are essential for survival and a positive outcome. Because inborn errors of metabolism are commonly thought to be "pediatric diseases", awareness of these conditions among physicians treating adults is often low. Diagnostic work-up including MS/MS-based acylcarnitine profiling in dried blood spots/plasma and organic acid analysis in urine should be initiated promptly in every patient with acidosis of unknown origin. Additionally, MADD should be ruled out in any patient with suggestive muscular symptoms. As in patients with milder disease variants symptoms are often intermittent and only become evident during periods of illness and catabolic stress, late-onset MADD might be underdiagnosed \[\[[@B29]\],\[[@B30]\]\]. Organic acid and acylcarnitine analyses should be performed as first-line investigations with a low degree of suspicion as they may prevent patients from more invasive investigations like liver or muscle biopsies.

![**Lipid storage myopathy.** Histological picture of lipid storage myopathy typical for late-onset MADD. **A** Oilred stain. **B** Trichrome stain. **C** Electron microscopy.](s13023-014-0117-5-3){#F3}

Making a biochemical diagnosis of late-onset MADD may be challenging in both symptomatic and asymptomatic individuals \[\[[@B31]\]\]. Most patients display a typical pattern of organic acids in urine and acylcarnitines in dried blood/plasma at least during metabolic decompensations. However, organic acid and acylcarnitine results may be unremarkable especially during metabolically stable conditions and in some cases even during catabolism \[\[[@B7]\],\[[@B9]\],\[[@B13]\],\[[@B19]\],\[[@B31]\]-\[[@B36]\]\]. Others show only selected abnormal metabolites, but not a full diagnostic pattern. Some therapeutic interventions like MCT oil, valproic acid or particular antibiotics (pivalic acid) can also mimic at least parts of the biochemical profile \[\[[@B37]\],\[[@B38]\]\]. Finally, due to common polymorphic alleles in the *ACADS* gene about 14% of the population will excrete ethylmalonic acid or will have elevated C4-acylcarnitine species in plasma \[\[[@B39]\]\]. This indicates, that MADD cannot be definitely excluded by a single metabolic screening test. The diagnosis should therefore rely on blood and urine analysis and ultimately be confirmed by molecular methods. In patients with muscular symptoms and histologically proven lipid storage myopathy but unremarkable metabolite patterns molecular analysis (starting with the *ETFDH* gene, followed by sequencing of *ETFA* and *ETFB*) is advisable.

Recently, several riboflavin transporters have been identified \[\[[@B40]\]-\[[@B42]\]\]: *SLC52A1* (RFT1), *SLC52A2* (RFT3) and *SLC52A3* (RFT2) are transmembrane proteins that mediate the cellular uptake of riboflavin \[\[[@B42]\]\]. Defects of these transporters lead to cellular riboflavin deficiency and may result in biochemical and clinical abnormalities mimicking MADD \[\[[@B43]\],\[[@B44]\]\]. Only one patient with a RFT1 defect has been identified so far \[\[[@B43]\]\]. This woman was clinically asymptomatic, but showed biochemical evidence of riboflavin deficiency. She was diagnosed after her daughter had presented with poor suck, hypoglycemia, and metabolic acidosis within the first days of life \[\[[@B45]\]\]. Other riboflavin transporter defects that can mimick mild MADD biochemically are the Brown-Vialetto-Van Laere (BVVL) and the Fazio Londe (FL) syndrome, two disorders which are nowadays considered to be the same disease entity \[\[[@B44]\],\[[@B46]\],\[[@B47]\]\]. These cases are due to mutations in the SLC52A2 or SLC52A3 genes which code for the RFT3 and RFT2 proteins, respectively. The clinical picture of these rare neurologic disorders usually differs from MADD and comprises sensorineural deafness (not in Fazio Londe syndrome), bulbar palsy, facial weakness and respiratory distress \[\[[@B44]\],\[[@B47]\]\]. However, a certain clinical overlap, especially with respect to the muscular symptoms, can make it difficult to distinguish late-onset MADD and BVVL/FL syndrome. It is well possible that some patients with genetic riboflavin transporter defects have been misdiagnosed with MADD. In particular, patients in whom no mutations in *ETFDH*, *ETFA* and *ETFB* can be identified should be investigated for a defective riboflavin transporter.

The positive clinical effects of riboflavin treatment are well documented as are the molecular mechanisms for riboflavin responsiveness \[\[[@B4]\],\[[@B7]\],\[[@B8]\],\[[@B29]\],\[[@B48]\],\[[@B49]\]\]. In particular, the chaperone effects that can compensate for inherited folding defects of ETFDH, have recently been described \[\[[@B49]\]\]. The vast majority of late-onset MADD patients respond very well to riboflavin. It has been shown that ETFDH deficiency may be associated with secondary coenzyme Q10 (Q10) deficiency. Thus, Q10 supplementation in addition to riboflavin treatment has been suggested \[\[[@B50]\]\]. The finding of *ETFDH* mutations in patients with the myopathic phenotype of Q10 deficiency initially lead to the suggestion that the late-onset form of MADD and the myopathic form of Q10 deficiency are allelic diseases \[\[[@B50]\]\]. However, in the meanwhile, late-onset MADD patients without Q10 deficiency have been reported contradicting this hypothesis \[\[[@B16]\]\]. Q10 deficiency has been found to be associated with increased mitochondrial production of reactive oxygen species (ROS) due to an electron leak of misfolded variant ETFDH proteins with impaired Q10 binding affinity \[\[[@B49]\],\[[@B51]\]\]. Based on studies with fibroblasts of six patients with riboflavin-responsive MADD Cornelius et al. have reported that Q10 treatment can decrease ROS production and may relieve oxidative stress. This suggests that late-onset MADD patients could benefit from a combined treatment of riboflavin and Q10 \[\[[@B52]\]\]. Q10 treatment alone is not advisable. Six Chinese patients, who were given Q10 alone before the diagnosis of late-onset MADD was made, showed only a mild response with their muscle strength never returning to normal \[\[[@B28]\]\]. Yamaguchi et al. studied the therapeutic effect of bezafibrate by an in vitro probe acylcarnitine assay using cultured fibroblasts of a patient with late-onset MADD \[\[[@B53]\]\]. The aberrantly elevated MADD-characteristic acylcarnitines were clearly corrected by the presence of bezafibrate in culture medium. Following these results, a clinical trial of bezafibrate was performed in the same patient, a 2-year-old boy, and resulted in a dramatical improve of his motor and cognitive skills in combination with a reduction of C4, C8, C10 and C12 acylcarnitines in blood and a normalization of the urinary organic acid profile. Notably, this boy has never been treated with riboflavin. Due to the loss of carnitine conjugates via the urine, MADD patients are prone to carnitine deficiency, which may require oral carnitine supplementation \[\[[@B5]\],\[[@B9]\]\]. Taken together, the mainstay of therapy in patients with late-onset MADD is riboflavin with excellent outcome data, and supplementation should be prompted immediately after diagnosis.

A clear genotype-phenotype correlation has been described for the different subtypes of MADD \[\[[@B54]\]\]: Homozygosity for null mutations is usually associated with MADD type 1, whereas even minor amounts of residual ETF/ETFDH activity seem to be sufficient to prevent embryonic development of congenital anomalies giving rise to type 2 disease. A relatively high residual activity is found in the late-onset form type 3 \[\[[@B54]\]\]. All patients with late-onset MADD of whom mutation data are published carry at least one missense variation, which may potentially result in some residual activity (Additional file [1](#S1){ref-type="supplementary-material"}: Table S1). The genotype-phenotype correlation within the group of late-onset patients, however, is poor. Apart from the disease-causing mutation other, especially exogenous, factors such as febrile infections, a restricted diet and other physiologic stressors may play an important role in the modulation of the clinical phenotype. Most mutations seem to be private. Three common mutations in the *ETFDH* gene have been described which are mainly found in the Chinese and Taiwanese population: c.250G \> A (p.A84T), c.770A \> G (p.Y257C), c.1227A \> C (p.L409F) \[\[[@B23]\],\[[@B28]\],\[[@B55]\]\]. As this literature review has shown, the vast majority of late-onset patients harbour mutations in the *ETFDH* gene, while *ETFA* or *ETFB* mutations are found in only about 7% of individuals. Therefore, mutation analysis in this cohort should first focus on *ETFDH*.

While early-onset MADD is a disease with high mortality, the prognosis of late-onset MADD seems to be good. Nevertheless, 5% of patients reported in the literature had died mainly during metabolic decompensations. In several patients, death could not be prevented despite the known diagnosis of MADD. Although most deaths occurred in childhood, several cases with fatal outcome during adolescence and adulthood have been described \[\[[@B22]\],\[[@B56]\]\]. Even patients who present with chronic symptoms in adulthood are prone to metabolic crises. To prevent unfavorable outcomes, patients need to be aware of the disease risks and potential triggers of decompensations. MADD represents an official target of newborn screening in only few countries, e.g. in the United States. Limited data exist on the detection rate of late-onset MADD by this approach. However, based on the number of detected cases so far, it is quite possible that most MADD patients are recognized by newborn screening \[\[[@B57]\]\]. Early diagnosis and treatment from the neonatal period might modify the clinical outcome and possibly even prevent symptoms in late-onset MADD patients.

In conclusion, late-onset MADD may be an underdiagnosed disease in adults with myopathy and should be considered early in the differential diagnosis. This may not only prevent patients from invasive diagnostic procedures such as muscle biopsies, but also help to avoid fatal metabolic decompensations.
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Clinical, biochemical and molecular data of 350 patients with late-onset multiple acyl-CoA dehydrogenase deficiency published in the literature between 1979 and 2014. Patient numbers in this supplemental table do not correspond to those displayed in Figure [1](#F1){ref-type="fig"}.
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